-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com
Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report released on Tuesday. The firm set a "sell" rating on the biotechnology company's stock.
Bellerophon Therapeutics Stock Performance
Shares of BLPH opened at $1.14 on Tuesday. The stock's 50-day simple moving average is $1.30 and its 200 day simple moving average is $1.39. Bellerophon Therapeutics has a 52-week low of $0.67 and a 52-week high of $4.49. The stock has a market capitalization of $10.88 million, a price-to-earnings ratio of -0.58 and a beta of -0.02.
Get Bellerophon Therapeutics alerts:Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last released its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.18. On average, research analysts forecast that Bellerophon Therapeutics will post -2.21 earnings per share for the current fiscal year.
Institutional Trading of Bellerophon Therapeutics
A hedge fund recently raised its stake in Bellerophon Therapeutics stock. Renaissance Technologies LLC raised its holdings in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) by 13.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 209,399 shares of the biotechnology company's stock after acquiring an additional 24,100 shares during the period. Renaissance Technologies LLC owned approximately 2.19% of Bellerophon Therapeutics worth $258,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.92% of the company's stock.About Bellerophon Therapeutics
(Get Rating)
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Read More
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- 3 Stocks Growing Their Businesses for 2023
- China-Based EV Maker BYD Set For Big European, Japanese Expansion
- Is Illumina Still the Gamechanger in Genomics Sequencing?
- Here's What Makes Amazon a Sum-of-All-Parts Commerce Juggernaut
- The Institutions Bought CarMax In Q3, Now It's Cheaper
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Stock analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report released on Tuesday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新闻网的股票分析师在周二发布的一份报告中假设了贝勒罗芬治疗公司(Bellerophon Treateutics)(纳斯达克代码：BLPH-GET Rating)的股票。该公司对这家生物技术公司的股票设定了“卖出”评级。
Bellerophon Therapeutics Stock Performance
贝勒罗芬治疗公司股票表现
Shares of BLPH opened at $1.14 on Tuesday. The stock's 50-day simple moving average is $1.30 and its 200 day simple moving average is $1.39. Bellerophon Therapeutics has a 52-week low of $0.67 and a 52-week high of $4.49. The stock has a market capitalization of $10.88 million, a price-to-earnings ratio of -0.58 and a beta of -0.02.
周二，BLPH的股价开盘报1.14美元。该股的50日简单移动均线切入位在1.30美元，200日简单移动均线切入位在1.39美元。贝勒罗芬治疗公司的股价为0.67美元，为52周低点，52周高点为4.49美元。该股市值为1,088万美元，市盈率为-0.58倍，贝塔系数为-0.02。
Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last released its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.18. On average, research analysts forecast that Bellerophon Therapeutics will post -2.21 earnings per share for the current fiscal year.
贝乐芬治疗公司(纳斯达克代码：BLPH-GET Rating)最近一次发布季度收益报告是在8月15日(星期一)。这家生物技术公司公布了本季度每股收益(0.43美元)，比普遍预期的(0.61美元)高出0.18美元。研究分析师平均预测，贝勒罗芬治疗公司本财年的每股收益将达到2.21美元。
Institutional Trading of Bellerophon Therapeutics
贝乐芬治疗药物的制度性交易
About Bellerophon Therapeutics
关于贝勒罗芬治疗公司
(Get Rating)
(获取评级)
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
贝勒罗芬治疗公司是一家临床阶段治疗公司，专注于在美国开发治疗心肺疾病的产品。其产品包括INOPulse，这是一种用于治疗肺动脉高压的专有脉冲式一氧化氮输送平台。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- 3 Stocks Growing Their Businesses for 2023
- China-Based EV Maker BYD Set For Big European, Japanese Expansion
- Is Illumina Still the Gamechanger in Genomics Sequencing?
- Here's What Makes Amazon a Sum-of-All-Parts Commerce Juggernaut
- The Institutions Bought CarMax In Q3, Now It's Cheaper
- 免费获取StockNews.com关于贝勒罗芬治疗(BLPH)的研究报告
- 2023年3只股票实现业务增长
- 中国电动汽车制造商比亚迪将在欧洲和日本大举扩张
- Illumina仍然是基因组测序中的Gamchanger吗？
- 以下是亚马逊成为一个集所有部分于一身的商务巨头的原因
- 这些机构在第三季度收购了CarMax，现在更便宜了
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受贝勒罗芬治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bellerophon治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧